Form 8-K - Current report:
SEC Accession No. 0000950170-23-019679
Filing Date
2023-05-09
Accepted
2023-05-09 16:13:08
Documents
15
Period of Report
2023-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20230509.htm   iXBRL 8-K 65695
2 EX-99.1 achv-ex99_1.htm EX-99 200370
3 GRAPHIC img9551541_0.jpg GRAPHIC 21022
  Complete submission text file 0000950170-23-019679.txt   466484

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT achv-20230509_def.xml EX-101.DEF 13919
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT achv-20230509_pre.xml EX-101.PRE 14084
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT achv-20230509_lab.xml EX-101.LAB 21357
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT achv-20230509.xsd EX-101.SCH 2939
9 EXTRACTED XBRL INSTANCE DOCUMENT achv-20230509_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 23902149
SIC: 2835 In Vitro & In Vivo Diagnostic Substances